AbbVie Inc. (NYSE:ABBV) rival Gilead makes exclusive deal with CVS for hep C drugs. The deal blocks North Chicago-based AbbVie Inc.’s treatment, called Viekira Pak, which will only be available to patients given approval because of medical exceptions or through a process called prior authorization, according to CVS. Patients already taking Viekira Pak will be allowed to finish their treatment. AbbVie Inc. (NYSE:ABBV) belongs to … Continue reading Market Movers: AbbVie Inc. (NYSE:ABBV), Morgan Stanley (NYSE:MS), Sanmina Corporation (NASDAQ:SANM), Advanced Semiconductor Engineering Inc. (NYSE:ASX), Resource Capital Corp. (NYSE:RSO)